| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DKK 1 |
| Uniprot No | O94907 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 32-266aa |
| 氨基酸序列 | TLNSVLNSNAIKNLPPPLGGAAGHPGSAVSAAPGILYPGGNKYQTIDNYQ PYPCAEDEECGTDEYCASPTRGGDAGVQICLACRKRRKRCMRHAMCCPGN YCKNGICVSSDQNHFRGEIEETITESFGNDHSTLDGYSRRTTLSSKMYHT KGQEGSVCLRSSDCASGLCCARHFWSKICKPVLKEGQVCTKHRRKGSHGL EIFQRCYCGEGLSCRIQKDHHQASNSSRLHTCQRH |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DKK1重组蛋白的3篇参考文献及其简要摘要：
---
1. **"DKK1 inhibits Wnt signaling in cancer by interfering with LRP6 receptor phosphorylation"**
- **作者**: Cruciat, C.M. et al.
- **摘要**: 该研究揭示了重组DKK1蛋白通过结合Wnt共受体LRP6.抑制其磷酸化及下游信号通路，从而在多种癌症模型中阻碍肿瘤细胞增殖并促进凋亡，为靶向Wnt通路的治疗策略提供依据。
2. **"Recombinant DKK1 regulates bone formation via antagonizing Wnt/β-catenin signaling"**
- **作者**: Li, X. et al.
- **摘要**: 通过体外和动物实验，证明重组DKK1蛋白通过抑制成骨细胞分化和骨形成，导致骨密度下降，提示其在骨质疏松等骨代谢疾病中的潜在病理作用及治疗靶点价值。
3. **"Production and functional characterization of recombinant human DKK1 in mammalian expression systems"**
- **作者**: Ke, H.Z. et al.
- **摘要**: 研究报道了在HEK293细胞中高效表达并纯化具有生物活性的重组人DKK1蛋白，验证其对Wnt信号通路的抑制能力，为后续机制研究和药物开发提供可靠工具。
---
以上文献覆盖了DKK1重组蛋白在癌症、骨代谢中的作用机制及生产方法，适用于不同研究方向的需求。
**Background of DKK1 Recombinant Protein**
DKK1 (Dickkopf-1) is a secreted glycoprotein belonging to the Dickkopf family, known for its role as a key regulator of the Wnt signaling pathway. It primarily inhibits the canonical Wnt/β-catenin pathway by binding to low-density lipoprotein receptor-related proteins 5/6 (LRP5/6), which are essential co-receptors for Wnt signaling. This interaction disrupts the formation of Wnt-Frizzled-LRP complexes, effectively suppressing downstream signaling cascades involved in cell proliferation, differentiation, and embryonic development. Dysregulation of DKK1 is implicated in various diseases, including cancer, bone disorders, and neurodegenerative conditions.
Recombinant DKK1 is produced using molecular cloning techniques, often expressed in mammalian cell systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, such as glycosylation, which are critical for its biological activity. The protein typically retains structural features of native DKK1. including two conserved cysteine-rich domains essential for receptor binding.
In research, recombinant DKK1 serves as a vital tool to study Wnt pathway mechanisms, stem cell differentiation, and disease pathogenesis. It is also explored for therapeutic applications, such as targeting Wnt-driven cancers or enhancing bone formation in osteoporosis. Additionally, DKK1 is studied as a diagnostic biomarker; elevated serum levels correlate with disease progression in multiple myeloma, rheumatoid arthritis, and liver fibrosis.
The production of high-purity, bioactive recombinant DKK1 ensures reproducibility in experimental and clinical settings, highlighting its importance in both basic science and translational medicine.
×
